Multiresistant-MRSA tricuspid valve infective endocarditis with ancient osteomyelitis locus
© Chesi et al; licensee BioMed Central Ltd. 2006
Received: 25 November 2005
Accepted: 26 July 2006
Published: 26 July 2006
Methicillin-resistant S. aureus (MRSA) with low susceptibility to glycopeptides is uncommon.
The case of a 50-year-old non-drug addict patient presenting with tricuspid valve infective endocarditis (IE) by MRSA resistant to vancomycin and linezolid is presented. There was response only to quinupristin/dalfopristin. He had a motorcycling accident four years before undergoing right above-the-knee amputation and orthopaedic fixation of the left limb. There were multiple episodes of left MRSA-osteomyelitis controlled after surgery and vancomycin therapy. MRSA isolated from the blood at the time of IE presented with the same profile than the isolated four years earlier. Sequential treatment with teicoplanin-cotrimoxazole and Linezolid associated to vancomycin – rifampicin – cotrimoxazole had no improvement. Infection was controlled after 28 days of therapy with quinupristin/dalfopristin.
The literature presents only a few cases of MRSA IE not susceptible to glycopeptides in not drug addicted patients. This case shows the comparison of a highly-resistant MRSA after previous S. aureus osteomyelitis treated with glycopeptides. This is the first description of successful treatment of resistant-MRSA IE of the tricuspid valve complicated by multiple pulmonary septic infarction with quinupristin/dalfopristin
Infective endocarditis was an invariably fatal infection before the availability of antimicrobials. A significant percentage of patients still succumb to it despite aggressive treatment especially when infected with virulent organisms such as Staphylococcus aureus. Overall, approximately 20% of S. aureus isolates in Europe are reported as methicillin-resistant, whereas in US hospitals the prevalence ranges from 33% to 55%. The past few years have also witnessed an increase in life-threatening community-acquired infections caused by MRSA. Most infections with VISA (vancomycin-intermediate S. aureus) and VRSA (vancomycin-resistant S. aureus) have occurred in a setting of heavy prior use of glycopeptides and other antimicrobial agents. Emergence of reduced vancomycin susceptibility and clinical resistance in S. aureus increases the possibility that currently available antimicrobial agents may become ineffective for treating systemic infections.
Summary of multiple events
Road Traffic accident
August 2000 – December 2000
Rehabilitation, Orthopaedic fixation, osteomyelitis left leg
Ciprofloxacin 500 mg/12 h/21 days
Amoxicillin/clavulanic acid 1 g/12 h/28 days
Minocycline 100 mg/12 h/14 days
Cotrimoxazole 480 mg./12 h/8 days
Teicoplanin 200 mg/24 h/8 days
Spontaneous limb fracture – Orthopaedic fixation
Teicoplanin 400 mg/24 h/8 days
Rifampicin 600 mg/12 h/10 days
February 2003 – May 2003
Autotransplantation of corticospongiosa
Ciprofloxacin 500/12 h/14 days
Teicoplanin 200 mg/24 h/8 days
June 2004 – August 2004
Internal Medicine Unit and Cardiac Surgery Unit
Tricuspid valve endocarditis
Cefixime 800 mg/2 days
Oxacillin 16 g/24 h/3 days + Gentamycin 240 mg/24 h/3 days
Teicoplanin 1200 mg/24 h/8 days + Cotrimoxazole 960 mg/24 h/8 days
Linezolid 600 mg/24 h/7 days
Vancomycin 3 g/24 h/12 days + Rifampicin 600 mg/24 h/12 days+ Cotrimoxazole 1440 mg/24 h/12 days
Quinupristin/dalfopristin 750 mg/8 h/36 days
The patient was treated with an association of oxacillin 16 gr/day and gentamycin 240 mg/day that was shifted two days later to teicoplanin (1200 mg/12 h/IV) for the first 3 days followed with 1200 mg/day/IV) and cotrimoxazole (480 mg/12 h/IV) as MRSA was isolated. The MRSA was resistant to clindamycin (MIC>8 mcg/ml), erythromycin (MIC>8 mcg/ml), gentamycin (MIC>16 mcg/ml), norfloxacin (MIC>16 mcg/ml), ofloxacin (MIC>8 mcg/ml), oxacillin (MIC>4 mcg/ml), penicillin (MIC>0.8 mcg/ml), and tobramycin (MIC>16 mcg/ml). The MRSA resulted susceptible to rifampicin (MIC<0.5 mcg/ml), teicoplanin (MIC<0.5 mcg/ml), tetracicline (MIC<1 mcg/ml), cotrimoxazole (MIC<10 mcg/ml) and vancomycin (MIC<1 mcg/ml). Linezolid 600 mg daily iv was started 8 days later because of worsening condition (Linezolid was not tested in-vitro). However this proved to be ineffective as the patient still presented fever and positive blood cultures for MRSA maintaining the same strains. A new TTE was performed showing the presence of a new vegetation on the anterior leaflet of the tricuspid valve.
Linezolid was then replaced with vancomycin (500 mg/6 h/IV), rifampicin (600 mg/8 h/IV) and cotrimoxazole (480 mg/8 h/IV) that was again ineffective and after 12 days of therapy was suspended. After 27 days of ineffective therapy the patient condition was very poor; TTE showed new vegetations on the posterior leaflet of the tricuspid valve with severe insufficiency and large pulmonary infarctions. Quinupristin/dalfopristin were at 7.5 mg-Kg/8 h/IV. After three days of therapy the patient became afebrile and his condition improved. After 25 days of therapy with quinupristin/dalfopristin, biological markers for infection became normal and the patient underwent left above-the-knee amputation as prevention treatment for new infections. The therapy with quinupristin/dalfopristin was suspended after 42 days. A Transesophageal echocardiography and a thoracic computed tomography scan were performed at the end of antibiotic therapy and at 18 months after discharge showed complete regression of the tricuspid vegetation, only mild valve insufficiency and absence of residual pulmonary infarction.
Infective endocarditis is an uncommon disease. A recent publication has shown that the incidence of IE is about 31 cases per million inhabitants. Right-sided IE represents 10% of all cases with tricuspid valve involvement in 90% of cases. Moss and Munt showed the right-sided IE is more frequent in drug-addicts (63%) [2, 3]. We present a case of tricuspid IE complicated by multiple pulmonary septic infarctions originated probably from a focus of chronic osteomyelitis. The interesting aspect of this case is not only the acute clinic presentation but also the high grade of clinical resistance to the different antibiotic regimens used . The patient did not respond to the use of glycopeptides, teicoplanin and vancomycin always in association with other drugs despite the positive in vitro susceptibility to these antibiotics . The use of linezolid , a wide spectrum antibiotic, with a very good reported action on the lungs  resulted ineffective with a concomitant dramatic deterioration of the clinical condition of the patient. The use of quinupristin/dalfopristin  as salvage therapy resulted in a very quick improvement after three days and resulted in complete cure of tricuspid valve IE and septic embolic lung abscesses. The antibiotic therapy was continued for four weeks as recommended by the American Heart Association guidelines  for complicated right-sided endocarditis diminishing the rate of relapses due. The decision to perform a left above-the-knee amputation was considered as the only possible guarantee of removal of chronic osteomyelitis focus and was performed with the patient on quinupristin/dalfopristin antibiotic treatment.
In this paper, we firstly reported a non-operated patient with tricuspid valve endocarditis by MRSA complicated by multiple pulmonary septic infarction cured with quinupristin/dalfopristin. The use of these antibiotic agents opens new perspectives in the management of severely ill patients with invasive valve endocarditis infection.
Methicillin-resistant S. aureus
minimal inhibitory concentration
- Hoen B, Alla F, Selton-Suty C, Beguinot I, Bouvet A, Briancon S, Casalta JP, Danchin N, Delahaye F, Etienne J, Le Moing V, Leport C, Mainardi JL, Ruimy R, Vandenesch F: Changing Profile of Infective Endocarditis. Result of a year survey in France. JAMA. 2002, 288: 75-81. 10.1001/jama.288.1.75.View ArticlePubMedGoogle Scholar
- Moss R, Munt B: Injection drug use and right side endocarditis. Heart. 2003, 89: 577-581. 10.1136/heart.89.5.577.View ArticlePubMedPubMed CentralGoogle Scholar
- Abraham J, Mansour C, Veledar E, Khan B, Lerakis S: Staphylococcus Aureus bacteremia and Endocarditis: the Grady Memorial Hospital experience with meticillin-sensitive S aureus and meticillin-resistant S aureus bacteremia. Am Heart J. 2004, 147: 536-539. 10.1016/j.ahj.2003.09.018.View ArticlePubMedGoogle Scholar
- Eliopoulos GM: Current and new antimicrobial agents. Am Heart J. 2004, 147: 587-592. 10.1016/j.ahj.2003.06.006.View ArticlePubMedGoogle Scholar
- Woods CW, Cheng AC, Fowler VG, Moorefield M, Frederick J, Sakoulas G, Meka VG, Tenover FC, Zwadyk P, Wilson KH: Endocarditis caused by Staphylococcus Aureus with reduced susceptibility to Vancomycin. Clini Infect Dis. 2004, 38: 1088-1091.Google Scholar
- Ruiz EM, Guerrero IC, Tuazon CU: Endocarditis caused by Methicillin resistant Staphylococcus Aureus : treatment failure with linezolid. Clin Infect Dis. 2002, 35: 1018-1020. 10.1086/342698.View ArticlePubMedGoogle Scholar
- Honeybourne D, Tobin C, Jevons G, Andrews J, Wise R: Intrapulmonary penetration of linezolid. J Antimicrob Chemother. 2003, 51: 1431-1434. 10.1093/jac/dkg262.View ArticlePubMedGoogle Scholar
- Drew RH, Perfect JR, Srinath L, Kurkimilis E, Dowzicky M, Talbot GH: Treatment of methicillin-resistant Staphylococcus aureus infections with quinupristin/dalfopristin in patients intolerant of or failing prior therapy. J Antimicrob Chemother. 2000, 16: 775-784. 10.1093/jac/46.5.775.View ArticleGoogle Scholar
- Bonow RO, Carabello B, de Leon AC, Edmunds LH, Fedderly BJ, Freed MD, Gaasch WH, McKay CR, Nishimura RA, O'Gara PT, O'Rourke RA, Rahimtoola SH, Ritchie JL, Cheitlin MD, Eagle KA, Gardner TJ, Garson A, Gibbons RJ, Russell RO, Ryan TJ, Smith SC: ACC/AHA Guidelines for the Management of Patients With Valvular Heart Disease. Executive Summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients With Valvular Heart Disease). J Heart Valve Dis. 1998, 7 (6): 672-707.PubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2334/6/124/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.